Abstract
Objective and Study Design: This multicentre, randomised, double-blind clinical trial compared the clinical and bacteriological efficacy and safety of cefuroxime axetil and amoxicillin/clavulanic acid in the treatment of secondary bacterial infections of acute bronchitis (SBIAB).
Patients and Methods: 312 patients with signs and symptoms of acute bronchitis were enrolled at 16 centres and randomised to receive either 5 days of treatment with cefuroxime axetil 250mg twice daily (n = 156) or 10 days of treatment with amoxicillin/clavulanic acid 875/125mg twice daily (n = 156). Patients were assessed once during treatment (3 to 5 days) and twice post-treatment (1 to 4 days and 11 to 14 days post-treatment).
Results: Organisms were isolated from pretreatment sputum specimens of 294 of 312 (94%) patients, common pathogens being Haemophilus parainfluenzae, H. influenzae, Moraxella catarrhalis and Streptococcus pneumoniae (39, 23, 9 and 8% of isolates, respectively). 33% of H. influenzae isolates and 88% of M. catarrhalis isolates produced β-lactamase. A satisfactory clinical outcome was achieved in 86% (114 of 133) and 90% (128 of 142) of the clinically evaluable patients treated with cefuroxime axetil or amoxicillin/clavulanic acid, respectively (p = 0.27), at the 11-to 14-day follow-up visit. A satisfactory bacteriological outcome was obtained in 89% (110 of 123) and 92% (123 of 134) of bacteriologically and clinically evaluable patients treated with cefuroxime axetil or amoxicillin/clavulanic acid, respectively (p = 0.516), at the 11-to 14-day follow-up visit. Amoxicillin/clavulanic acid treatment was associated with a greater incidence of drug-related adverse events (32 vs 12%, p < 0.001), particularly gastrointestinal adverse events (23 vs 4%, p < 0.001), than was cefuroxime axetil treatment.
Conclusions: Cefuroxime axetil 250mg twice daily for 5 days has similar efficacy to amoxicillin/clavulanic acid 875/125mg twice daily for 10 days in the treatment of acute bronchitis, and produces fewer drug-related adverse events.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hueston WJ, Mainous AG, 3rd. Acute bronchitis. Am Fam Phys 1998; 57: 1270–6, 1281-72
Gleckman R. Acute bronchitis. In: Rakel R, editor. Conn’s current therapy. Philadelphia: WB Saunders Co., 1998
Vogel F. A guide to the treatment of lower respiratory tract infections. Drugs 1995; 50: 62–72
Oeffinger KC, Snell LM, Foster BM, et al. Diagnosis of acute bronchitis in adults: a national survey of family physicians. J Fam Pract 1997; 45: 402–9
Oeffinger KC, Snell LM, Foster BM, et al. Treatment of acute bronchitis in adults. A national survey of family physicians. J Fam Pract 1998; 46: 469–75
Doern GV, Brueggemann AB, Pierce G, et al. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40: 2884–6
Doern GV, Brueggemann AB, Pierce G, et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother 1997; 41: 292–7
Doern GV, Brueggemann A, Holley Jr HP, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40: 1208–3
Henry D, Ruoff GE, Rhudy J, et al. Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis. Antimicrob Agents Chemother 1995; 39: 2528–4
Ball P, Geddes A, Rolinson G. Amoxycillin clavulanate: an assessment after 15 years of clinical application. J Chemother 1997; 9: 167–98
NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Approved Standard M7-A4 (ISBN 1-56238-309-4). Wayne, PA: National Committee for Clinical Laboratory Standards, 1997
Arthur M, McAdoo M, Guerra J, et al. Clinical comparison of cefuroxime axetil with cefixime in the treatment of acute bronchitis. Am J Ther 1996; 3: 622–9
Langan C, Clecner B, Cazzola CM, et al. Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis. Int J Clin Pract 1998; 52: 289–97
Pakes GE, Graham JA, Rauch AM, et al. Cefuroxime axetil in the treatment of sinusitis. A review. Arch Fam Med 1994; 3: 165–75
Henry D, Ruoff GE, Rhudy J, et al. Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with secondary bacterial infections of acute bronchitis. Clin Ther 1995; 17: 861–74
Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect Agents Dis 1994; 3: 266–73
Reyes H, Guiscafre H, Munoz O, et al. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol 1997; 50: 1297–304
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Henry, D.C., Ruoff, G.E., Noonan, M. et al. Comparison of the Efficacy and Tolerability of Short-Course Cefuroxime Axetil and Amoxicillin/Clavulanic Acid in the Treatment of Secondary Bacterial Infections of Acute Bronchitis. Clin. Drug Investig. 18, 335–344 (1999). https://doi.org/10.2165/00044011-199918050-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-199918050-00001